Evaluation of Real Imaging's 3D Functional Metabolic Imaging and Risk Assessment (MIRA) System

Breast Cancer Clinical Trial

Official title:

Evaluation of Real Imaging's 3d Functional Metabolic Imaging and Risk Assessment (Mira) System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02155075
• Other study ID #: 960-CSP-ISR_ImplantsMC_ILS3
• Status: Recruiting
• Phase: N/A
• Start date: January 2015
• Est. completion date: October 2019

Study information

• Verified date: June 2018
• Source: Real Imaging Ltd.
• Contact: MIri Sklair-Levy, MD
• Phone: 972-3-5302514
• Email: Miri.SklairLevy[@]sheba.health.gov.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Three-dimensional functional Metabolic Imaging (3D MIRA) is a new infrared imaging technology using the Real Imager 8 (RI8) developed by Real Imaging. This technology generates 3D metabolic maps of the breast and based on sophisticated machine learning technology, provides objective risk assessment for the presence of malignant tumor in the breast. The procedure is non-invasive, comfortable and does not involve ionizing radiation. It is based on acquiring infrared images of the breast. Those images are processed and analyzed by computers to provide the objective risk assessment.

The technology is intended to be used as a screening tool for breast cancer and emerges as highly useful in women for whom screening mammography is sub-optimal, such as women with dense breast. 3D MIRA is unaffected by breast density and is therefore ideal for evaluating patients with mammographically dense breasts.

The purpose of this clinical study is to assess the ability of this novel technology to detect breast cancer in women.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 730
• Est. completion date: October 2019
• Est. primary completion date: October 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 30 Years and older

Eligibility

PHASE 1:

INCLUSION CRITERIA

1. Female

2. Woman has read, understood and signed the inform consent form

3. Age: 30 years and older

4. A. Women who are scheduled to undergo routine Mammography and/or US and/or MRI screening OR B. Women summoned for breast biopsy following a suspicious finding in recent screening exam and was graded 4/5 on BI-RADS scale

EXCLUSION CRITERIA:

1. Women who have had a Mammography and/or US and/or MRI examination performed on the day of the study prior to MIRA scan

2. Women who had undergone mastectomy and/or breast reconstruction

3. Women who have had a breast biopsy performed throughout the 6 weeks preceding the study

4. Women who have a fever on the day of the MIRA imaging

5. Women who are pregnant

6. Women who are breast-feeding

7. Women with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices in the chest area

8. Women who are unable to read, understand and execute written informed consent

9. Women who are currently undergoing chemotherapy and/or radiotherapy

PHASE 2:

ARM 1:

INCLUSION CRITERIA

1. Female

2. Age: 30 years and older

3. A. Asymptomatic women who are scheduled to undergo routine screening mammography or routine screening mammography and US Or B. Subjects scheduled for image-guided needle biopsy as a result of findings obtained during standard of care imaging modalities (mammography, ultrasound and/or MRI).

5. Women whose most recent prior mammogram was interpreted as heterogeneously dense (ACR BI-RADS Breast Density C) or extremely dense (ACR BI-RADS Breast Density D).

EXCLUSION CRITERIA:

1. Subjects who have had a Mammography and/or US and/or MRI examination performed on the day of the study prior to MIRA scan

2. Subjects scheduled for a diagnostic mammography due to a suspicious lump

3. Subjects who had undergone mastectomy and/or breast reconstruction

4. Subjects who have undergone breast reduction or breast augmentation.

5. Subjects who have large breast scar / breast deformation.

6. Subjects who have significant existing breast trauma.

7. Subjects who have undergone lumpectomy

8. Subjects who have had a breast needle biopsy performed throughout the 6 weeks preceding the study

9. Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices in the chest area

10. Subjects with known Raynaud's Disease.

11. Subjects who have a fever on the day of the MIRA imaging

12. Subjects who are pregnant

13. Subjects who are breast-feeding

14. Subjects with known Mastitis

15. Subjects who are currently undergoing chemotherapy and/or radiotherapy

16. Subjects with contraindication to bilateral mammography or MRI.

17. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.

18. Subjects currently participating in another clinical study.

19. Subjects who are unable to read, understand and execute written informed consent

ARM 2:

INCLUSION CRITERIA:

1. Female

2. Age: 30 years and older

3. Asymptomatic women who are scheduled to undergo routine screening mammography or routine screening mammography and US

EXCLUSION CRITERIA :

1. Subjects who have had a Mammography examination performed on the day of the study prior to MIRA scan

2. Subjects scheduled for a diagnostic mammography due to a suspicious lump

3. Subjects who have had a breast biopsy performed throughout the 6 weeks preceding the study

4. Subjects who have a fever on the day of the MIRA imaging

5. Subjects who are pregnant

6. Subjects who are breast-feeding

7. Subjects with known Mastitis

8. Subjects with known Raynaud's Disease.

9. Subjects who are currently undergoing chemotherapy and/or radiotherapy

10. Subjects with contraindication to bilateral mammography

11. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.

12. Subjects currently participating in another clinical study.

13. Subjects who are unable to read, understand and execute written informed consent

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Device:
• MIRA device imaging
MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result

Locations

Country	Name	City	State
Israel	The Chaim Sheba Medical Center at Tel Hashomer	Ramat-Gan

Sponsors (1)

Lead Sponsor	Collaborator
Real Imaging Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sufficient number of cancer case and controls have been imaged	As this is a data collection study, end point will be reached when approximately 50 women with breast cancer and 100 healthy women (controls) are imaged by the device and sufficient for the comparison statistical analysis.	up to 24 months